OraSure Technologies (OSUR)
Market Price (3/11/2026): $3.19 | Market Cap: $232.9 MilSector: Health Care | Industry: Health Care Equipment
OraSure Technologies (OSUR)
Market Price (3/11/2026): $3.19Market Cap: $232.9 MilSector: Health CareIndustry: Health Care Equipment
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -89% | Weak multi-year price returns2Y Excs Rtn is -89%, 3Y Excs Rtn is -119% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -64 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -51% |
| Megatrend and thematic driversMegatrends include Biotechnology & Genomics, Precision Medicine, and Digital Health & Telemedicine. Themes include Advanced Diagnostics, Show more. | Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -44%, Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -19%, Rev Chg QQuarterly Revenue Change % is -32% | |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -32%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -35% | ||
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -31% | ||
| Key risksOSUR key risks include [1] the potential failure of its pivotal Sherlock CT/NG test launch and [2] declining revenues across its core businesses coupled with ongoing cash burn. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -89% |
| Megatrend and thematic driversMegatrends include Biotechnology & Genomics, Precision Medicine, and Digital Health & Telemedicine. Themes include Advanced Diagnostics, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -89%, 3Y Excs Rtn is -119% |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -64 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -51% |
| Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -44%, Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -19%, Rev Chg QQuarterly Revenue Change % is -32% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -32%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -35% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -31% |
| Key risksOSUR key risks include [1] the potential failure of its pivotal Sherlock CT/NG test launch and [2] declining revenues across its core businesses coupled with ongoing cash burn. |
Qualitative Assessment
AI Analysis | Feedback
OraSure Technologies (OSUR) stock has gained about 30% since 11/30/2025 because of the following key factors:
1. Anticipated Revenue Growth from New Product Launches and Regulatory Approvals. OraSure Technologies submitted two applications to the U.S. Food and Drug Administration (FDA) in December 2025 for a rapid molecular self-test for chlamydia and gonorrhea (CT/NG) and the Colli-Pee at-home urine collection device for sexually transmitted infections, with both products targeted for mid-2026 launches as key growth catalysts. Additionally, the OraQuick HIV Self-Test received authorization from Health Canada, becoming Canada's first oral HIV self-test, indicating an expansion in market reach. These regulatory advancements and upcoming product introductions have likely fueled investor optimism regarding future revenue streams beyond the declining COVID-19 related sales.
2. Stronger-than-Expected Core Business Performance in Q4 2025. OraSure reported Q4 2025 total revenue of $26.8 million, surpassing the midpoint of its guidance. Notably, core revenue, which excludes COVID-19 products, stood at $26.7 million, also exceeding guidance. The company also demonstrated an improvement in its GAAP gross margin to 41.0% in Q4 2025, up from 36.2% in Q4 2024, suggesting improving operational efficiency in its core segments. This performance indicated a stabilization in key segments, signaling a potential return to growth in 2026.
Show more
1. Anticipated Revenue Growth from New Product Launches and Regulatory Approvals. OraSure Technologies submitted two applications to the U.S. Food and Drug Administration (FDA) in December 2025 for a rapid molecular self-test for chlamydia and gonorrhea (CT/NG) and the Colli-Pee at-home urine collection device for sexually transmitted infections, with both products targeted for mid-2026 launches as key growth catalysts. Additionally, the OraQuick HIV Self-Test received authorization from Health Canada, becoming Canada's first oral HIV self-test, indicating an expansion in market reach. These regulatory advancements and upcoming product introductions have likely fueled investor optimism regarding future revenue streams beyond the declining COVID-19 related sales.
2. Stronger-than-Expected Core Business Performance in Q4 2025. OraSure reported Q4 2025 total revenue of $26.8 million, surpassing the midpoint of its guidance. Notably, core revenue, which excludes COVID-19 products, stood at $26.7 million, also exceeding guidance. The company also demonstrated an improvement in its GAAP gross margin to 41.0% in Q4 2025, up from 36.2% in Q4 2024, suggesting improving operational efficiency in its core segments. This performance indicated a stabilization in key segments, signaling a potential return to growth in 2026.
Show more
Stock Movement Drivers
Fundamental Drivers
The 31.5% change in OSUR stock from 11/30/2025 to 3/10/2026 was primarily driven by a 31.5% change in the company's P/S Multiple.| (LTM values as of) | 11302025 | 3102026 | Change |
|---|---|---|---|
| Stock Price ($) | 2.38 | 3.13 | 31.5% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 126 | 126 | 0.0% |
| P/S Multiple | 1.4 | 1.8 | 31.5% |
| Shares Outstanding (Mil) | 73 | 73 | 0.0% |
| Cumulative Contribution | 31.5% |
Market Drivers
11/30/2025 to 3/10/2026| Return | Correlation | |
|---|---|---|
| OSUR | 31.5% | |
| Market (SPY) | -0.9% | 16.0% |
| Sector (XLV) | -2.9% | 21.0% |
Fundamental Drivers
The -5.4% change in OSUR stock from 8/31/2025 to 3/10/2026 was primarily driven by a -9.3% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 8312025 | 3102026 | Change |
|---|---|---|---|
| Stock Price ($) | 3.31 | 3.13 | -5.4% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 139 | 126 | -9.3% |
| P/S Multiple | 1.8 | 1.8 | 2.1% |
| Shares Outstanding (Mil) | 75 | 73 | 2.1% |
| Cumulative Contribution | -5.4% |
Market Drivers
8/31/2025 to 3/10/2026| Return | Correlation | |
|---|---|---|
| OSUR | -5.4% | |
| Market (SPY) | 5.3% | 34.6% |
| Sector (XLV) | 11.9% | 24.6% |
Fundamental Drivers
The -10.1% change in OSUR stock from 2/28/2025 to 3/10/2026 was primarily driven by a -43.9% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 2282025 | 3102026 | Change |
|---|---|---|---|
| Stock Price ($) | 3.48 | 3.13 | -10.1% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 224 | 126 | -43.9% |
| P/S Multiple | 1.2 | 1.8 | 57.1% |
| Shares Outstanding (Mil) | 75 | 73 | 2.2% |
| Cumulative Contribution | -10.1% |
Market Drivers
2/28/2025 to 3/10/2026| Return | Correlation | |
|---|---|---|
| OSUR | -10.1% | |
| Market (SPY) | 15.0% | 40.7% |
| Sector (XLV) | 4.2% | 38.3% |
Fundamental Drivers
The -50.4% change in OSUR stock from 2/28/2023 to 3/10/2026 was primarily driven by a -61.7% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 2282023 | 3102026 | Change |
|---|---|---|---|
| Stock Price ($) | 6.31 | 3.13 | -50.4% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 328 | 126 | -61.7% |
| P/S Multiple | 1.4 | 1.8 | 30.1% |
| Shares Outstanding (Mil) | 73 | 73 | -0.5% |
| Cumulative Contribution | -50.4% |
Market Drivers
2/28/2023 to 3/10/2026| Return | Correlation | |
|---|---|---|
| OSUR | -50.4% | |
| Market (SPY) | 77.3% | 30.8% |
| Sector (XLV) | 26.0% | 29.8% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| OSUR Return | -18% | -45% | 70% | -56% | -33% | 32% | -70% |
| Peers Return | 31% | -16% | 2% | 14% | 5% | -1% | 34% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | -1% | 81% |
Monthly Win Rates [3] | |||||||
| OSUR Win Rate | 50% | 42% | 50% | 8% | 42% | 100% | |
| Peers Win Rate | 65% | 45% | 57% | 60% | 52% | 47% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 33% | |
Max Drawdowns [4] | |||||||
| OSUR Max Drawdown | -22% | -69% | -9% | -56% | -42% | -2% | |
| Peers Max Drawdown | -9% | -42% | -24% | -19% | -12% | -13% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -2% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: EW, MASI, UFPT, ATRC, ABT.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 3/10/2026 (YTD)
How Low Can It Go
| Event | OSUR | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -82.4% | -25.4% |
| % Gain to Breakeven | 469.0% | 34.1% |
| Time to Breakeven | Not Fully Recovered days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -47.7% | -33.9% |
| % Gain to Breakeven | 91.3% | 51.3% |
| Time to Breakeven | Not Fully Recovered days | 148 days |
| 2018 Correction | ||
| % Loss | -71.2% | -19.8% |
| % Gain to Breakeven | 247.2% | 24.7% |
| Time to Breakeven | Not Fully Recovered days | 120 days |
| 2008 Global Financial Crisis | ||
| % Loss | -78.6% | -56.8% |
| % Gain to Breakeven | 367.6% | 131.3% |
| Time to Breakeven | 1,045 days | 1,480 days |
Compare to EW, MASI, UFPT, ATRC, ABT
In The Past
OraSure Technologies's stock fell -82.4% during the 2022 Inflation Shock from a high on 2/1/2021. A -82.4% loss requires a 469.0% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About OraSure Technologies (OSUR)
OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. It operates in two segments, Diagnostics and Molecular Solutions. The company's principal products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D. saliva alcohol test. It also offers genomic products under the Oragene and ORAcollect brands; microbiome collection products; and GenoFIND genomics laboratory services. In addition, the company provides ORAcollect, RNA and OMNIgene, and RAL collection devices for use in connection with COVID-19 molecular testing; offers Colli-Pee collection device for the volumetric collection of first void urine; and manufactures and sells kits that are used to collect, stabilize, transport, and store samples of genetic material for molecular testing in the academic research and commercial applications, including ancestry, disease risk management, lifestyle, and animal testing. Further, it provides other diagnostic products, such as immunoassays and other in vitro diagnostic tests. The company markets its products to clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, and commercial and industrial entities. OraSure Technologies, Inc. was incorporated in 2000 and is headquartered in Bethlehem, Pennsylvania.
AI Analysis | Feedback
Here are 1-2 brief analogies for OraSure Technologies (OSUR):
- Like a specialized Abbott Laboratories focused on rapid, non-invasive diagnostic tests.
- Imagine a more focused Thermo Fisher Scientific that develops diagnostic tools and unique sample collection technologies.
AI Analysis | Feedback
- OraQuick® HIV Tests: Rapid oral fluid tests for the detection of HIV-1 and HIV-2 antibodies, available for both professional and self-testing use.
- InteliSwab™ COVID-19 Rapid Test: A self-administered rapid antigen test that provides accurate results for the qualitative detection of SARS-CoV-2.
- Oral Fluid Collection Devices (e.g., OraSure® Intercept®): Non-invasive devices for collecting oral fluid samples, primarily used in drugs of abuse testing.
- Molecular Sample Collection Devices (e.g., OMNIgene®, ORAcollect®): Non-invasive devices designed for collecting and stabilizing DNA, RNA, and microbial samples for genomics and diagnostics.
AI Analysis | Feedback
OraSure Technologies (OSUR) primarily sells its diagnostic products and molecular collection devices to other companies and organizations rather than directly to individuals. While the company does not disclose specific major customer names in its public filings, as no single customer accounts for 10% or more of its consolidated net revenues, its major customer categories include:
-
Healthcare Providers and Clinical Laboratories
This category encompasses hospitals, clinics, physicians' offices, and clinical laboratories. These customers utilize OraSure's range of diagnostic tests (e.g., for HIV, HCV, and COVID-19) and molecular sample collection devices for patient care, screening, and comprehensive diagnostic testing.
-
Public Health and Government Entities
This includes various public health organizations, government agencies, and community-based organizations. These entities leverage OraSure's products for disease surveillance, public health programs, large-scale testing initiatives, and in institutional settings such as correctional facilities.
-
Research Institutions and Biotechnology Companies
Through its Molecular Solutions division (DNA Genotek, Diversigen), OraSure provides advanced sample collection devices and specialized genomics/microbiome services. Its customers in this category include academic research institutions, pharmaceutical companies, and other biotechnology firms engaged in scientific studies, clinical trials, and research and development.
-
Distributors and Retail Channels
OraSure also distributes its products through a network of other distributors, pharmacies, and directly to consumers via e-commerce and retail channels. This channel is particularly significant for over-the-counter products, such as COVID-19 home tests, enabling broader market access for individuals.
AI Analysis | Feedback
nullAI Analysis | Feedback
Carrie Eglinton Manner, President and Chief Executive Officer Carrie Eglinton Manner was appointed President and Chief Executive Officer of OraSure Technologies in June 2022, bringing over 25 years of healthcare leadership and transformation expertise. Prior to joining OraSure, she served as Senior Vice President, Advanced & General Diagnostics Clinical Solutions, at Quest Diagnostics, where she was responsible for launching innovative diagnostic solutions and led the molecular genetics team in pioneering next-generation sequencing innovation. Before her tenure at Quest Diagnostics, Ms. Eglinton Manner spent two decades at GE Healthcare, holding various leadership roles, including President and CEO of multiple distinct business units with global engineering and manufacturing responsibilities. She holds a B.S. degree in mechanical engineering from the University of Notre Dame. Kenneth J. McGrath, Chief Financial Officer Kenneth J. McGrath was named Chief Financial Officer in August 2022, overseeing finance, accounting, tax, and information technology for OraSure Technologies. Before joining OraSure, Mr. McGrath spent eight years at Quest Diagnostics, most recently as Vice President in Finance, where he led an organization managing over $7 billion in revenue and helped build Quest's Advanced Diagnostics business. His career also includes various finance leadership positions at Johnson & Johnson, Inc., and he began his professional journey as an engineer at Ford Motor Company. Mr. McGrath holds an M.B.A from the University of Michigan and a B.S. from the University of Notre Dame, and he is a CFA Charterholder. Michele Anthony, Senior Vice President, Controller, and Chief Accounting Officer Michele Anthony serves as Senior Vice President, Controller, and Chief Accounting Officer at OraSure Technologies. Anne Messing, Chief Commercial Officer Anne Messing is the Chief Commercial Officer at OraSure Technologies. David Rappaport, CFA, Senior Vice President, Corporate Development, Strategy and Integration David Rappaport is the Senior Vice President, Corporate Development, Strategy and Integration at OraSure Technologies. He is also a CFA Charterholder.AI Analysis | Feedback
The key risks to OraSure Technologies (OSUR) include the potential failure of a crucial new product launch, a trend of declining revenues across its core business segments coupled with ongoing cash burn, and significant uncertainties surrounding public health funding.
- Failure of the Sherlock CT/NG Testing Kit Launch: The successful launch and market adoption of the Sherlock CT/NG testing kit are considered the "single most important catalyst" for OraSure Technologies' turnaround, with its failure representing the "largest risk" to the company. The future of OraSure is heavily dependent on the success of this at-home STD test kit, including its FDA approval and market penetration.
- Declining Core Business Revenues and Cash Burn: OraSure Technologies has experienced a substantial decline in revenue across its Diagnostics and Sample Management Solutions segments following the COVID-19 pandemic. This decline is attributed to decreased international HIV revenues, reduced domestic orders, and the loss of a significant consumer genomics customer. As a result, the company is "burning cash" as it attempts to stabilize and grow its business.
- Uncertainty in Public Health Funding: OraSure Technologies faces ongoing challenges due to "elevated levels of uncertainty related to funding for public health programs and research as well as the government shutdown in the U.S." This funding instability is expected to contribute to a decline in both international and U.S. Diagnostics revenue for the company.
AI Analysis | Feedback
nullAI Analysis | Feedback
OraSure Technologies (OSUR) operates in several distinct markets with varying addressable market sizes:- HIV Self-Testing: The global HIV self-testing market was estimated at USD 211.55 million in 2024 and is projected to reach USD 643.41 million by 2033. North America held the largest revenue share of 33.40% in this market in 2024, with the U.S. being the leading country in the North American market.
- Microbiome Products and Services: The global microbiome market was expected to grow from approximately $325 million in 2017 to $725 million or more in 2022.
- Infectious Disease Diagnostics (Overall): The global infectious disease in-vitro diagnostics market size is estimated at USD 28.10 billion in 2025 and is forecasted to reach approximately USD 34.87 billion by 2034. The North American market for in-vitro diagnostics for infectious diseases surpassed USD 10.70 billion in 2024. Specifically, the U.S. infectious disease in-vitro diagnostics market was valued at USD 7.49 billion in 2024 and is projected to reach around USD 9.71 billion by 2034.
- Point-of-Care (POC) Diagnostics: The global point-of-care diagnostics market was valued at approximately $37.5 billion in 2023 and is projected to reach approximately $50 billion by 2028.
- Sexually Transmitted Infection (STI) Testing: OraSure's acquisition of Sherlock Biosciences targets the $1.5 billion STI testing market, specifically for rapid, at-home molecular diagnostics for Chlamydia and gonorrhea.
AI Analysis | Feedback
OraSure Technologies (OSUR) is expected to drive future revenue growth over the next 2-3 years through several key initiatives:
-
New Product Launches and Strategic Acquisitions: OraSure is focused on new product developments expected in 2025 and 2026. The acquisition of Sherlock Biosciences is anticipated to expand its innovation pipeline with an advanced molecular diagnostics platform for rapid self-testing, initially targeting conditions such as chlamydia and gonorrhea (CTNG). Additionally, the acquisition of BioMedomics is set to enhance OraSure's diagnostic portfolio with the Sickle SCAN rapid test for sickle cell disease, leveraging existing international sales channels.
-
Expansion and Diversification of Customer Base and Market Penetration: The company aims to strengthen existing customer relationships and establish new ones, thereby expanding the markets served by its rapid diagnostics. This includes driving multi-product sales across its portfolio of HIV, HCV, and Syphilis tests. Diversifying the customer base and product portfolio is a key part of the company's growth strategy.
-
Sustained Performance and Recovery in International HIV Diagnostics: OraSure has experienced strong order trends in its international HIV business, contributing to year-over-year diagnostics revenue growth. Despite some anticipated moderation due to changes in national health program funding in 2025, the underlying demand and preference for their oral fluid testing internationally are expected to support continued revenue generation.
-
Growth of Core Business Segments, including Sample Management Solutions: The company anticipates a return to year-over-year core revenue growth in the fourth quarter of 2024. While the sample management business has faced some headwinds, excluding specific customer impacts, this segment is positioned for positive year-over-year growth, indicating a gradual recovery in key end markets.
AI Analysis | Feedback
Share Repurchases
- OraSure Technologies authorized a $40 million stock repurchase program in March 2025, to be funded from cash on hand over a 24-month period.
- The company deployed $5 million to repurchase approximately 1.5 million shares of its common stock in Q3 2025.
- An additional $5 million was deployed during Q2 2025 to repurchase 1.8 million shares of common stock.
Share Issuance
- On May 14, 2025, stockholders approved an amendment to the Stock Award Plan, increasing the shares authorized for issuance by 6,000,000.
Outbound Investments
- OraSure signed a definitive agreement to acquire BioMedomics, which will enhance its diagnostic portfolio with the Sickle SCAN test for sickle cell disease.
- The company deployed $5.0 million for the acquisition of Sherlock Biosciences during Q4 2024.
- OraSure made a $30.0 million investment in Sapphiros, as reported in the Form 10-K filing for the fiscal year ended December 31, 2024.
Capital Expenditures
- Capital expenditures in the last twelve months (as of November 5, 2025) totaled -$3.73 million.
- Projected capital expenditures are $12 million for 2025, $13 million for 2026, and $15 million for 2027.
- A primary focus of capital expenditures includes investments in the Sherlock platform, the CTNG clinical trial, and other innovation projects, with $10 million allocated for innovation investments in Q4 2025, including $7 million to $8 million for Sherlock-related developments.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| OraSure Technologies Earnings Notes | 12/16/2025 | |
| OraSure Technologies Stock Jump Looks Great, But How Secure Is That Gain? | 10/17/2025 |
| Title | |
|---|---|
| ARTICLES |
Trade Ideas
Select ideas related to OSUR.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 02282026 | QDEL | QuidelOrtho | Insider | Insider Buys 45DStrong Insider BuyingCompanies with multiple insider buys in the last 45 days | 0.0% | 0.0% | 0.0% |
| 02272026 | CHE | Chemed | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 02272026 | LLY | Eli Lilly | Monopoly | MY | Getting CheaperMonopoly-Like with P/S DeclineLarge cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple | 0.0% | 0.0% | 0.0% |
| 02202026 | HAE | Haemonetics | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 3.5% | 3.5% | 0.0% |
| 02132026 | IQV | IQVIA | Dip Buy | DB | P/E OPMDip Buy with Low PE and High MarginBuying dips for companies with tame PE and meaningfully high operating margin | 7.1% | 7.1% | -3.0% |
| 02282018 | OSUR | OraSure Technologies | Quality | Q | Momentum | UpsideQuality Stocks with Momentum and UpsideBuying quality stocks with strong momentum but still having room to run | -5.9% | -37.7% | -44.2% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 98.16 |
| Mkt Cap | 5.4 |
| Rev LTM | 1,065 |
| Op Inc LTM | 203 |
| FCF LTM | 136 |
| FCF 3Y Avg | 87 |
| CFO LTM | 155 |
| CFO 3Y Avg | 118 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 10.5% |
| Rev Chg 3Y Avg | 5.8% |
| Rev Chg Q | 8.2% |
| QoQ Delta Rev Chg LTM | 2.0% |
| Op Mgn LTM | 16.8% |
| Op Mgn 3Y Avg | 14.5% |
| QoQ Delta Op Mgn LTM | 0.0% |
| CFO/Rev LTM | 14.8% |
| CFO/Rev 3Y Avg | 12.4% |
| FCF/Rev LTM | 12.9% |
| FCF/Rev 3Y Avg | 9.4% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 5.4 |
| P/S | 3.5 |
| P/EBIT | 19.7 |
| P/E | 10.2 |
| P/CFO | 22.3 |
| Total Yield | 0.7% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | 2.3% |
| D/E | 0.1 |
| Net D/E | -0.0 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | 4.4% |
| 3M Rtn | 2.6% |
| 6M Rtn | -0.6% |
| 12M Rtn | -4.4% |
| 3Y Rtn | 8.5% |
| 1M Excs Rtn | 6.5% |
| 3M Excs Rtn | 0.5% |
| 6M Excs Rtn | -4.1% |
| 12M Excs Rtn | -24.0% |
| 3Y Excs Rtn | -67.2% |
Segment Financials
Revenue by Segment| $ Mil | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Coronavirus disease 2019 (COVID-19) | 258 | 243 | |||
| Human immunodeficiency virus (HIV) | 61 | 39 | |||
| Sample Management Solutions | 54 | 63 | |||
| Hepatitis C virus (HCV) | 13 | 13 | |||
| Risk assessment testing | 10 | 10 | |||
| Molecular Services | 4 | 7 | |||
| Non-product and services revenues | 3 | 9 | |||
| Other product and service revenues | 2 | 2 | |||
| Diagnostics | 78 | ||||
| Molecular Solutions | 76 | ||||
| Total | 405 | 387 | 155 |
Price Behavior
Price Behavior
| Market Price | $3.13 | |
| Market Cap ($ Bil) | 0.2 | |
| First Trading Date | 03/17/1992 | |
| Distance from 52W High | -14.5% | |
| 50 Days | 200 Days | |
| DMA Price | $2.76 | $2.86 |
| DMA Trend | indeterminate | up |
| Distance from DMA | 13.3% | 9.5% |
| 3M | 1YR | |
| Volatility | 47.4% | 50.7% |
| Downside Capture | -39.98 | 119.44 |
| Upside Capture | 102.95 | 88.01 |
| Correlation (SPY) | 15.4% | 42.0% |
OSUR Betas & Captures as of 2/28/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 0.56 | 1.15 | 1.06 | 1.60 | 1.16 | 1.09 |
| Up Beta | -0.89 | 1.06 | 0.87 | 1.18 | 1.04 | 1.12 |
| Down Beta | 2.95 | 2.45 | 1.95 | 2.77 | 1.33 | 1.21 |
| Up Capture | 146% | 179% | 169% | 99% | 106% | 44% |
| Bmk +ve Days | 9 | 20 | 31 | 70 | 142 | 431 |
| Stock +ve Days | 9 | 20 | 32 | 60 | 120 | 353 |
| Down Capture | -102% | -67% | -22% | 129% | 114% | 106% |
| Bmk -ve Days | 12 | 21 | 30 | 54 | 109 | 320 |
| Stock -ve Days | 9 | 18 | 26 | 58 | 121 | 373 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with OSUR | |
|---|---|---|---|---|
| OSUR | -10.1% | 50.9% | -0.04 | - |
| Sector ETF (XLV) | 4.0% | 17.5% | 0.07 | 38.9% |
| Equity (SPY) | 18.7% | 19.1% | 0.77 | 42.1% |
| Gold (GLD) | 79.6% | 26.2% | 2.22 | 4.6% |
| Commodities (DBC) | 19.2% | 17.2% | 0.88 | 13.6% |
| Real Estate (VNQ) | 5.3% | 16.4% | 0.14 | 40.0% |
| Bitcoin (BTCUSD) | -20.4% | 45.5% | -0.36 | 16.2% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with OSUR | |
|---|---|---|---|---|
| OSUR | -22.4% | 54.8% | -0.25 | - |
| Sector ETF (XLV) | 8.0% | 14.5% | 0.37 | 31.1% |
| Equity (SPY) | 13.7% | 17.0% | 0.64 | 32.6% |
| Gold (GLD) | 24.5% | 17.2% | 1.16 | 4.6% |
| Commodities (DBC) | 11.6% | 19.0% | 0.50 | 5.5% |
| Real Estate (VNQ) | 5.3% | 18.8% | 0.19 | 28.1% |
| Bitcoin (BTCUSD) | 6.5% | 56.8% | 0.33 | 14.6% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with OSUR | |
|---|---|---|---|---|
| OSUR | -7.2% | 56.7% | 0.11 | - |
| Sector ETF (XLV) | 10.3% | 16.5% | 0.51 | 31.6% |
| Equity (SPY) | 14.9% | 17.8% | 0.72 | 29.2% |
| Gold (GLD) | 15.1% | 15.6% | 0.81 | 1.0% |
| Commodities (DBC) | 8.9% | 17.6% | 0.42 | 6.6% |
| Real Estate (VNQ) | 5.9% | 20.7% | 0.25 | 19.0% |
| Bitcoin (BTCUSD) | 66.0% | 66.8% | 1.05 | 6.4% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 2/25/2026 | 10.0% | 7.5% | |
| 11/5/2025 | -6.6% | -3.9% | -4.3% |
| 8/5/2025 | -8.5% | -10.3% | 1.0% |
| 5/7/2025 | -6.8% | -10.8% | 3.6% |
| 2/25/2025 | -23.5% | -15.7% | -15.2% |
| 11/6/2024 | -3.6% | -8.0% | -11.1% |
| 8/6/2024 | 0.5% | -3.7% | 3.5% |
| 5/8/2024 | -5.0% | 1.4% | -11.7% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 12 | 9 | 9 |
| # Negative | 11 | 14 | 13 |
| Median Positive | 4.2% | 18.3% | 19.8% |
| Median Negative | -6.8% | -9.8% | -15.2% |
| Max Positive | 32.3% | 40.5% | 43.4% |
| Max Negative | -33.1% | -29.6% | -45.2% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 09/30/2025 | 11/05/2025 | 10-Q |
| 06/30/2025 | 08/06/2025 | 10-Q |
| 03/31/2025 | 05/07/2025 | 10-Q |
| 12/31/2024 | 03/07/2025 | 10-K |
| 09/30/2024 | 11/06/2024 | 10-Q |
| 06/30/2024 | 08/06/2024 | 10-Q |
| 03/31/2024 | 05/09/2024 | 10-Q |
| 12/31/2023 | 03/11/2024 | 10-K |
| 09/30/2023 | 11/08/2023 | 10-Q |
| 06/30/2023 | 08/04/2023 | 10-Q |
| 03/31/2023 | 05/10/2023 | 10-Q |
| 12/31/2022 | 03/03/2023 | 10-K |
| 09/30/2022 | 11/08/2022 | 10-Q |
| 06/30/2022 | 08/09/2022 | 10-Q |
| 03/31/2022 | 05/10/2022 | 10-Q |
| 12/31/2021 | 03/01/2022 | 10-K |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.